http://www.biocentury.com/rss/biotech-pharma-newsThe Bernstein Report on BioBusiness feedsen-US© Copyright 2012 BioCentury, Inc.RSS Generatorhttp://www.biocentury.com/Data/NewsCenter2/Images/biotech-pharma-news/CoverStory.gifhttp://www.biocentury.com/rss/biotech-pharma-newshttp://www.biocentury.com/biotech-pharma-news/coverstory/2012-05-14/despite-potential-rems-hurdles-arenas-lorcaserin-could-fill-niche-in-obesity-a1http://www.biocentury.com/biotech-pharma-news/coverstory/2012-05-14/despite-potential-rems-hurdles-arenas-lorcaserin-could-fill-niche-in-obesity-a1Cover StoryArena's lorcaserin could carve out a niche in obesity despite limited efficacy and potential hurdles to use, including an FDA committee's call for baseline and annual echocardiograms.Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/analysts/2012-05-14/analyst-picks-and-changes-07http://www.biocentury.com/biotech-pharma-news/analysts/2012-05-14/analyst-picks-and-changes-07Analyst Picks & ChangesAnalyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/11 cls AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) Baird Christopher Raymond Downgrade Neutral (from outperform) -16% $13.25 Ladenburg …Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-14/galecto-developing-galectin-3-inhibitors-for-idiopathic-pulmonary-fibrosis-a11http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-14/galecto-developing-galectin-3-inhibitors-for-idiopathic-pulmonary-fibrosis-a11Emerging Company ProfileGalecto is developing galectin-3 inhibitors targeting both macrophages and fibroblasts, which it expects to provide potent inhibition of fibrosis in IPF by itself and in combination with other compounds.Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-14/galecto-two-pronged-attack-sidebar-galecto-biotech-ab-corporate-profile-01http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-14/galecto-two-pronged-attack-sidebar-galecto-biotech-ab-corporate-profile-01Emerging Company ProfileGalecto: Two-pronged attack Galecto Biotech AB Lund, Sweden Technology: Galectin modulators Disease focus: Pulmonary, inflammation, cancer Clinical status: Preclinical Founded: 2011 by Hakon Leffler, Ulf Nilsson…Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-14/visionary-sights-on-drug-design-sidebar-visionary-pharmaceuticals-inc-corporate-profile-02http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-14/visionary-sights-on-drug-design-sidebar-visionary-pharmaceuticals-inc-corporate-profile-02Emerging Company ProfileVisionary: Sights on drug design Visionary Pharmaceuticals Inc. San Diego, Calif. Technology: Structure-based drug design Disease focus: Autoimmune, inflammation Clinical status: Preclinical Founded: 2010 by …Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-14/visionary-using-structure-based-design-to-discover-small-molecules-a12http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-14/visionary-using-structure-based-design-to-discover-small-molecules-a12Emerging Company ProfileVisionary believes a large library and computational technology that accounts for conformational changes will allow it to design more drug-like small molecules than those discovered by conventional HTS.Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/actelion-to-focus-on-specialty-indications-investors-wanted-more-details-a17bhttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/actelion-to-focus-on-specialty-indications-investors-wanted-more-details-a17bFinanceEbb & Flow More details, please Investors were underwhelmed last week after Actelion Ltd. (SIX:ATLN) outlined plans to return to earnings growth. Actelion fell CHF0.80 to CHF39.10, after gaining 14% the prior week …Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/bb-biotech-boosts-intercell-with-eur25m-in-equity-and-debt-with-royalty-twist-a17dhttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/bb-biotech-boosts-intercell-with-eur25m-in-equity-and-debt-with-royalty-twist-a17dFinanceEbb & Flow Royalties don't dilute Swiss biotech investor BB Biotech AG (SIX:BION; Xetra:BBZA) expects Intercell AG (VSE:ICLL; OTCQX:INRLY) to reach profitability with last week's infusion of €25 million ($32.5 …Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/ebb-and-flow-figure-money-raised-in-2012-05http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/ebb-and-flow-figure-money-raised-in-2012-05FinanceVertex the odds-on favorite Money Raised in 2012 Last week, the biotech industry raised $310 million, bringing to $11.6 billion the total raised year-to-date. In 2011, a total of $49.5 billion was raised, including…Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/ebb-and-flow-table-earnings-on-deck-04http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/ebb-and-flow-table-earnings-on-deck-04FinanceVertex the odds-on favorite Earnings on deck At least three biotechs and pharmas are slated to report earnings this week. Chinese biosimilars play 3SBio Inc. (NASDAQ:SSRX) is expected to report a 33% jump in …Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/ebb-and-flow-table-eps-watch-06http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/ebb-and-flow-table-eps-watch-06FinanceVertex the odds-on favorite EPS watch At least 13 biotechs and pharmas reported earnings last week. While not yet profitable, Dendreon Corp. (NASDAQ:DNDN) lost a fifth of its valuation, or $335 million, after it did…Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/ebb-and-flow-table-thinning-the-pipeline-03http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/ebb-and-flow-table-thinning-the-pipeline-03FinanceVertex the odds-on favorite Thinning the pipeline Actelion Ltd. (SIX:ATLN) last week said it plans to focus R&D on specialty products, including Orphan diseases, immunomodulators and antibiotics, and out-license …Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/life-sciences-debt-provider-oxford-finance-raises-271m-in-bond-offering-a17chttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/life-sciences-debt-provider-oxford-finance-raises-271m-in-bond-offering-a17cFinanceEbb & Flow Life sciences leverage Oxford Finance LLC has leveraged a deep-pocketed parent company and consistent returns from issuing debt to development-stage life sciences companies to amass $530 million in new …Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/regulatory-clinical-and-other-milestones-a17fhttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/regulatory-clinical-and-other-milestones-a17fFinanceEbb & Flow Regulatory milestones Arena Pharmaceuticals Inc. (NASDAQ:ARNA) was up $3.77 (146%) to $6.36 last week, including a $2.70 (74%) jump on Friday after an FDA panel voted 18-4, with one abstention, that the …Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/tel-aviv-exchange-with-bids-for-us-listed-life-science-plays-analyst-research-a17ehttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/tel-aviv-exchange-with-bids-for-us-listed-life-science-plays-analyst-research-a17eFinanceEbb & Flow The lure of research The Tel Aviv Stock Exchange is planning to provide analyst research reports for its listed life sciences companies as part of an effort to attract dual-listings for U.S. companies on …Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/wall-street-more-than-doubles-vertex-valuation-on-odds-of-bigger-cf-franchise-a17ahttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-14/wall-street-more-than-doubles-vertex-valuation-on-odds-of-bigger-cf-franchise-a17aFinanceTable: Thinning the pipeline Table: Earnings on deck Figure: Money Raised in 2012 Table: EPS watch Investors think there's still room to …Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/regulation/2012-05-14/despite-potential-rems-hurdles-arenas-lorcaserin-could-fill-niche-in-obesity-a1http://www.biocentury.com/biotech-pharma-news/regulation/2012-05-14/despite-potential-rems-hurdles-arenas-lorcaserin-could-fill-niche-in-obesity-a1RegulationArena's lorcaserin could carve out a niche in obesity despite limited efficacy and potential hurdles to use, including an FDA committee's call for baseline and annual echocardiograms.Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/regulation/2012-05-14/next-issue-for-gileads-truvada-to-prevent-hiv-what-rems-will-fda-require-a15http://www.biocentury.com/biotech-pharma-news/regulation/2012-05-14/next-issue-for-gileads-truvada-to-prevent-hiv-what-rems-will-fda-require-a15RegulationNow that an FDA panel voted to recommend Truvada to prevent HIV, the next step is for FDA and Gilead to address calls for a strict REMS, including potential mandates for HIV testing.Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/regulation/2012-05-14/pfizer-radiographic-data-show-challenge-in-proving-effect-on-progression-of-ra-a13http://www.biocentury.com/biotech-pharma-news/regulation/2012-05-14/pfizer-radiographic-data-show-challenge-in-proving-effect-on-progression-of-ra-a13RegulationCompanies may need to enlarge and enrich placebo groups in RA trials to show significance on radiographic endpoints, given ethical concerns that limit how long patients can be on placebo.Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2012-05-14/how-new-randd-head-hayden-plans-to-remake-tevas-discovery-global-partnering-a6http://www.biocentury.com/biotech-pharma-news/strategy/2012-05-14/how-new-randd-head-hayden-plans-to-remake-tevas-discovery-global-partnering-a6StrategyMichael Hayden, Teva's new president of global R&D, plans to integrate generics and branded development, beef up efforts in discovery and personalized medicines, and partner with academics, charities and biotechs.Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2012-05-14/how-payers-pharmas-are-experimenting-with-outcomes-based-reimbursement-a8http://www.biocentury.com/biotech-pharma-news/strategy/2012-05-14/how-payers-pharmas-are-experimenting-with-outcomes-based-reimbursement-a8StrategyA handful of health plans and pharma companies are experimenting with new contracting models that tie reimbursement to health outcomes instead of drug volumes.Mon, 14 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2012-05-07/actelions-agenda-after-macitentans-success-in-make-or-break-phase-iii-for-pah-a1http://www.biocentury.com/biotech-pharma-news/coverstory/2012-05-07/actelions-agenda-after-macitentans-success-in-make-or-break-phase-iii-for-pah-a1Cover StoryActelion's agenda after Macitentan's success in make-or-break Phase III for PAHMon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/analysts/2012-05-07/analyst-picks-and-changes-05http://www.biocentury.com/biotech-pharma-news/analysts/2012-05-07/analyst-picks-and-changes-05Analyst Picks & ChangesAnalyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/4 cls Actelion Ltd. (SIX:ATLN) UBS Guillaume van Renterghem Price target Buy 18% CHF39.90 van Renterghem raised his target to CHF61…Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-07/essa-a-baby-cougar-sidebar-essa-pharma-inc-corporate-profile-01http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-07/essa-a-baby-cougar-sidebar-essa-pharma-inc-corporate-profile-01Emerging Company ProfileEssa: A baby Cougar Essa Pharma Inc. Vancouver, B.C. Technology: Small molecule inhibitor of the N-terminus of the androgen receptor Disease focus: Cancer Clinical status: Preclinical Founded: 2009 by Marianne …Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-07/essas-epi-0011-kills-prostate-tumors-other-androgen-targeting-agents-dont-a9http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-07/essas-epi-0011-kills-prostate-tumors-other-androgen-targeting-agents-dont-a9Emerging Company ProfileEssa is developing a next-generation androgen receptor antagonist that blocks a previously intractable domain, a strategy the company expects to work even after other drugs have failed.Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-07/principia-developing-reversible-inhibitors-for-cancer-autoimmune-diseases-a10http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-07/principia-developing-reversible-inhibitors-for-cancer-autoimmune-diseases-a10Emerging Company ProfilePrincipia is developing small molecule reversible covalent inhibitors it believes will have fewer off-target effects and lower immunogenicity than irreversible inhibitors.Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-07/principia-reversing-covalency-sidebar-principia-biopharma-inc-corporate-profile-02http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-05-07/principia-reversing-covalency-sidebar-principia-biopharma-inc-corporate-profile-02Emerging Company ProfilePrincipia: Reversing covalency Principia Biopharma Inc. South San Francisco, Calif. Technology: Covalent reversible inhibitors using a reactive cyanoacrylamide group Disease focus: Cancer, Autoimmune Clinical …Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/abn-amro-reacquires-transaction-groups-to-expand-healthcare-banking-in-europe-a15chttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/abn-amro-reacquires-transaction-groups-to-expand-healthcare-banking-in-europe-a15cFinanceEbb & Flow Back together again Dutch bank ABN AMRO Bank N.V. has reacquired the M&A, advisory, equity brokerage and capital structuring capabilities in the Netherlands that it sold in 2007 to a consortium led by the…Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/bg-12-deal-keeps-on-giving-table-earnings-on-deck-03http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/bg-12-deal-keeps-on-giving-table-earnings-on-deck-03FinanceEbb & Flow Earnings on deck At least 10 biotechs and pharmas are slated to report earnings this week. Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Simcere Pharmaceutical Group (NYSE:SCR) and Teva Pharmaceutical …Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/biotech-investor-banker-and-analyst-personnel-changes-a15dhttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/biotech-investor-banker-and-analyst-personnel-changes-a15dFinanceEbb & Flow Venture tracks Scott Morenstein was promoted to managing director at Valence Life Sciences. He was principal at Caxton Advantage Venture Partners. Valence was formed in February by the founders of Caxton.…Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/calculating-the-upside-in-bg-12-earn-out-royalty-pharma-buys-into-ms-sales-a15ahttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/calculating-the-upside-in-bg-12-earn-out-royalty-pharma-buys-into-ms-sales-a15aFinanceTable: Earnings on deck Figure: Money raised in 2012 Table: EPS Watch The former shareholders of Fumapharm AG could be looking forward to …Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/dark-pool-liquidnet-woos-small-biotechs-with-access-to-institutional-investors-a13http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/dark-pool-liquidnet-woos-small-biotechs-with-access-to-institutional-investors-a13FinanceLiquidnet, a dark pool trading platform, is targeting small cap healthcare companies with its data on demand for shares and ability to place large blocks with long-only institutional funds.Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/ebb-and-flow-figure-money-raised-in-2012-04http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/ebb-and-flow-figure-money-raised-in-2012-04FinanceEbb & Flow Money Raised in 2012 Last week, the biotech industry raised $200 million, bringing to $11.4 billion the total raised year-to-date. In 2011, a total of $49.5 billion was raised, including $37.2 billion in …Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/ebb-and-flow-table-eps-watch-06http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/ebb-and-flow-table-eps-watch-06FinanceEbb & Flow EPS watch At least 22 biotechs and pharmas reported earnings last week, with 16 losing more than $9.3 billion in aggregate market value. Twelve of the 16 companies reported EPS and/or revenues that missed…Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/ibts-biotech-manda-exits-pile-up-now-ardea-eusa-a15bhttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/ibts-biotech-manda-exits-pile-up-now-ardea-eusa-a15bFinanceEbb & Flow Trusting in M&A International Biotechnology Trust plc (LSE:IBT) has been particularly successful riding the recent wave of biotech M&A. Last month's proposed deals for specialty pharma EUSA Pharma Inc. …Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/regulatory-clinical-and-other-milestones-a15ehttp://www.biocentury.com/biotech-pharma-news/finance/2012-05-07/regulatory-clinical-and-other-milestones-a15eFinanceEbb & Flow Regulatory milestones Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $1.33 (11%) to $13.77 last week after FDA accepted for review an NDA for lomitapide to treat homozygous familial …Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/politics/2012-05-07/pcori-revising-conflict-rules-as-it-begins-comparative-effectiveness-grants-a11http://www.biocentury.com/biotech-pharma-news/politics/2012-05-07/pcori-revising-conflict-rules-as-it-begins-comparative-effectiveness-grants-a11Politics and PolicyPCORI says it will issue new conflict of interest standards before it begins to award contracts for primary research into comparative effectiveness this month.Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2012-05-07/actelions-agenda-after-macitentans-success-in-make-or-break-phase-iii-for-pah-a1http://www.biocentury.com/biotech-pharma-news/strategy/2012-05-07/actelions-agenda-after-macitentans-success-in-make-or-break-phase-iii-for-pah-a1StrategyActelion's agenda after Macitentan's success in make-or-break Phase III for PAHMon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2012-05-07/jazz-continues-specialty-acquisition-strategy-but-will-shift-focus-to-randd-buys-a4http://www.biocentury.com/biotech-pharma-news/strategy/2012-05-07/jazz-continues-specialty-acquisition-strategy-but-will-shift-focus-to-randd-buys-a4StrategyJazz plans to use its revenue-generating track record to woo specialty acquisition candidates with development stage assets.Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/tech/2012-05-07/millennium-using-presages-mouse-platform-to-characterize-combo-cancer-therapies-a7http://www.biocentury.com/biotech-pharma-news/tech/2012-05-07/millennium-using-presages-mouse-platform-to-characterize-combo-cancer-therapies-a7Tools & TechniquesTakeda's Millennium subsidiary is using an in vivo screening platform from Presage to speed up preclinical characterization of cancer combination therapies.Mon, 07 May 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2012-04-30/gilead-bms-may-go-separate-ways-in-hcv-despite-100-svr-rate-in-phase-iia-a1http://www.biocentury.com/biotech-pharma-news/coverstory/2012-04-30/gilead-bms-may-go-separate-ways-in-hcv-despite-100-svr-rate-in-phase-iia-a1Cover StoryWhile combining BMS's daclatasvir and Gilead's GS-7977 produced a 100% SVR rate in a Phase II study, the two may eschew the opportunity to be first with a pan-genotypic HCV therapy. A split would increase technology …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/analysts/2012-04-30/analyst-picks-and-changes-08http://www.biocentury.com/biotech-pharma-news/analysts/2012-04-30/analyst-picks-and-changes-08Analyst Picks & ChangesAnalyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/27 cls Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Brean Murray Jonathan Aschoff Price target Buy -1% $90.56 Jefferies Eun Yang …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-30/ariel-antagonizing-pain-sidebar-ariel-pharmaceuticals-inc-corporate-profile-02http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-30/ariel-antagonizing-pain-sidebar-ariel-pharmaceuticals-inc-corporate-profile-02Emerging Company ProfileAriel: Antagonizing pain Ariel Pharmaceuticals Inc. Broomfield, Colo. Technology: Prostaglandin E2 (PGE2) receptor EP4 subtype (prostanoid EP4 receptor; PTGER4) antagonists Disease focus: Neurology Clinical …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-30/ariel-developing-ptger4-antagonists-for-acute-migraine-osteoarthritis-a13http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-30/ariel-developing-ptger4-antagonists-for-acute-migraine-osteoarthritis-a13Emerging Company ProfileAriel is developing a PTGER4 antagonist that it believes could be safer than standards of care for migraine and osteoarthritis, while also being effective in nonresponders to SOC.Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-30/vascular-magnetics-a-long-term-force-sidebar-vascular-magnetics-inc-corporate-profile-03http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-30/vascular-magnetics-a-long-term-force-sidebar-vascular-magnetics-inc-corporate-profile-03Emerging Company ProfileVascular Magnetics: A long-term force Vascular Magnetics Inc. Philadelphia, Pa. Technology: Drug-loaded magnetic particles delivered via a superparamagnetic catheter and external magnetic field Disease focus: Drug…Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-30/vascular-magnetics-developing-magnetically-delivered-paclitaxel-for-pad-a14http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-30/vascular-magnetics-developing-magnetically-delivered-paclitaxel-for-pad-a14Emerging Company ProfileVascular Magnetics is developing its Vascular Magnetics Intervention system for targeted delivery of sustained doses of anti-restenotic drugs in patients with peripheral artery disease.Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/biotech-investor-banker-and-analyst-personnel-changes-a15ehttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/biotech-investor-banker-and-analyst-personnel-changes-a15eFinanceEbb & Flow Analyst tracks Joshua Schimmer departed Leerink Swann, where he was a managing director and biotechnology research analyst. Banker tracks Michael Manocchio was promoted to VP from associate at Morgan …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/ebb-and-flow-figure-convergence-04http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/ebb-and-flow-figure-convergence-04FinanceEbb & Flow Convergence Amgen Inc. (NASDAQ:AMGN) and new partner AstraZeneca plc (LSE:AZN; NYSE:AZN) are crossing paths in more ways than one.The biotech gained $2.5 billion in market cap to $56.7 billion last week, …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/ebb-and-flow-figure-money-raised-in-2012-06http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/ebb-and-flow-figure-money-raised-in-2012-06FinanceEbb & Flow Money Raised in 2012 Last week, the biotech industry raised $175 million, bringing to $11.1 billion the total raised year-to-date. In 2011, a total of $49.5 billion was raised, including $37.2 billion in …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/ebb-and-flow-table-earnings-on-deck-05http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/ebb-and-flow-table-earnings-on-deck-05FinanceEbb & Flow Earnings on deck At least 18 profitable biotechs and pharmas are slated to report earnings this week. The Street is projecting double-digit EPS growth for specialty pharmas Allergan Inc. (NYSE:AGN) and …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/ebb-and-flow-table-eps-watch-07http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/ebb-and-flow-table-eps-watch-07FinanceEbb & Flow EPS watch At least 27 biotechs and pharmas reported earnings last week. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), both with newly launched drugs, tacked …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/fidelity-growth-partners-asia-raising-250m-fund-for-healthcare-consumer-it-a15chttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/fidelity-growth-partners-asia-raising-250m-fund-for-healthcare-consumer-it-a15cFinanceEbb & Flow Long view on China Fidelity Growth Partners Asia thinks longer can be better in Chinese investments, and expects a single LP, global reach and an established presence will allow it to take an extended …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/foresite-marks-first-liquidity-event-for-its-late-stage-life-science-portfolio-a15bhttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/foresite-marks-first-liquidity-event-for-its-late-stage-life-science-portfolio-a15bFinanceEbb & Flow Foreseeing liquidity Foresite Capital has made five investments since its launch last summer, one of which became liquid about a week ago using the Form 10 pathway, the firm's founder and CEO, Jim …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/how-amgens-700m-for-mustafa-nevzat-compares-to-other-generic-injectable-plays-a15ahttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/how-amgens-700m-for-mustafa-nevzat-compares-to-other-generic-injectable-plays-a15aFinanceEbb & Flow Turkish injection Figure: Convergence Table: Earnings on deck Figure: Money Raised in 2012 Table: EPS watch For the second April in a row, Amgen Inc. (NASDAQ:AMGN) has dipped into an emerging market …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/investors-not-buying-into-achillions-story-on-hcv-data-at-easl-a15dhttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/investors-not-buying-into-achillions-story-on-hcv-data-at-easl-a15dFinanceEbb & Flow Retelling doesn't help Achillion Pharmaceuticals Inc.'s HCV data presentation at the European Association for the Study of the Liver conference did not stanch the biotech's eroding share price, nor did …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/regulatory-clinical-and-other-milestones-a15fhttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-30/regulatory-clinical-and-other-milestones-a15fFinanceEbb & Flow Regulatory milestones Alimera Sciences Inc. (NASDAQ:ALIM) jumped $0.75 (28%) to $3.44 on Tuesday after the Austrian Agency for Health and Food Safety approved Iluvien to treat chronic diabetic macular …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/products/2012-04-30/beyond-statins-ldl-diversity-table-pcsk9-pipeline-01http://www.biocentury.com/biotech-pharma-news/products/2012-04-30/beyond-statins-ldl-diversity-table-pcsk9-pipeline-01Product Discovery & DevelopmentBeyond statins: LDL diversity PCSK9 pipeline Selected products targeting proprotein convertase subtilisin/kexin 9 (PCSK9) to treat hypercholesterolemia. Source: BCIQ: BioCentury Online Intelligence Company Product…Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/products/2012-04-30/beyond-statins-pcsk9-inhibitors-slash-ldl-but-not-for-all-patients-a7http://www.biocentury.com/biotech-pharma-news/products/2012-04-30/beyond-statins-pcsk9-inhibitors-slash-ldl-but-not-for-all-patients-a7Product Discovery & DevelopmentMost next-generation lipid-lowering drugs are being developed as add-ons to high-dose statins in patients who have not hit LDL goals. New data suggest different mechanisms may be appropriate for different populations.Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/products/2012-04-30/small-molecules-rnai-enter-clinic-in-race-to-target-pcsk9-for-lipid-lowering-a10http://www.biocentury.com/biotech-pharma-news/products/2012-04-30/small-molecules-rnai-enter-clinic-in-race-to-target-pcsk9-for-lipid-lowering-a10Product Discovery & DevelopmentWhile antibody inhibitors of PCSK9 have begun to report proof-of-concept data, other ways to inhibiting the target include small molecules and RNAi-based approaches.Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-30/epigenetics-epizyme-celgene-constellation-genentech-reflect-different-goals-a5http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-30/epigenetics-epizyme-celgene-constellation-genentech-reflect-different-goals-a5StrategyWhile the Epizyme-Celgene deal has similarities to the deal struck by Constellation and Genentech, the pacts are structured differently because the smaller biotechs have different visions for their future.Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-30/gilead-bms-may-go-separate-ways-in-hcv-despite-100-svr-rate-in-phase-iia-a1http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-30/gilead-bms-may-go-separate-ways-in-hcv-despite-100-svr-rate-in-phase-iia-a1StrategyWhile combining BMS's daclatasvir and Gilead's GS-7977 produced a 100% SVR rate in a Phase II study, the two may eschew the opportunity to be first with a pan-genotypic HCV therapy. A split would increase technology …Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/tech/2012-04-30/astrazeneca-accesses-conformetrixs-nmr-technolgy-to-find-compound-structures-a12http://www.biocentury.com/biotech-pharma-news/tech/2012-04-30/astrazeneca-accesses-conformetrixs-nmr-technolgy-to-find-compound-structures-a12Tools & TechniquesAstraZeneca has concluded that Conformetrix has perfected an NMR-based technology to quickly and accurately determine bioactive conformations of compounds in solution.Mon, 30 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2012-04-23/evaluating-three-options-for-human-genome-in-wake-of-takeout-bid-by-gsk-a1http://www.biocentury.com/biotech-pharma-news/coverstory/2012-04-23/evaluating-three-options-for-human-genome-in-wake-of-takeout-bid-by-gsk-a1Cover StoryHolding out for more money from GSK seems the most likely scenario for Human Genome Sciences, given the small value ascribed to the biotech's assets outside the partnership and the faint hope for a white knight.Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/analysts/2012-04-23/analyst-picks-and-changes-06http://www.biocentury.com/biotech-pharma-news/analysts/2012-04-23/analyst-picks-and-changes-06Analyst Picks & ChangesAnalyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/20 cls Endocyte Inc. (NASDAQ:ECYT) Baird Christopher Raymond Price target Neutral 95% $7.41 Leerink Howard Liang Price target …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/coverstory/2012-04-23/a-couple-of-bucks-more-table-hgs-pipeline-01http://www.biocentury.com/biotech-pharma-news/coverstory/2012-04-23/a-couple-of-bucks-more-table-hgs-pipeline-01Cover StoryA couple of bucks more HGS pipeline Like its marketed lupus treatment Benlysta belimumab, many of the clinical programs at Human Genome Sciences Inc. (NASDAQ:HGSI) are partnered with suitor GlaxoSmithKline plc (LSE:…Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-23/apim-besting-the-stress-defense-sidebar-apim-therapeutics-as-corporate-profile-02http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-23/apim-besting-the-stress-defense-sidebar-apim-therapeutics-as-corporate-profile-02Emerging Company ProfileAPIM: Besting the stress defense APIM Therapeutics A/S Trondheim, Norway Technology: Peptide-based inhibitors of proliferating cell nuclear antigen (PCNA) Disease focus: Cancer Clinical status: Preclinical …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-23/apim-targeting-cancer-cell-stress-defenses-to-treat-multiple-myeloma-a9http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-23/apim-targeting-cancer-cell-stress-defenses-to-treat-multiple-myeloma-a9Emerging Company ProfileAPIM is targeting a master switch that regulates cellular stress responses to increase the efficacy of multiple myeloma therapies.Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-23/hitting-the-links-sidebar-prolynx-llc-corporate-profile-03http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-23/hitting-the-links-sidebar-prolynx-llc-corporate-profile-03Emerging Company ProfileHitting the links ProLynx LLC Hayward, Calif. Technology: Linkers for carrier-drug conjugates Disease focus: Drug delivery, endocrine/metabolic, cancer Clinical status: Preclinical Founded: 2009 by Gary Ashley …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-23/prolynxs-linker-technology-releases-drugs-at-pre-programmed-rates-a10http://www.biocentury.com/biotech-pharma-news/emergingcompany/2012-04-23/prolynxs-linker-technology-releases-drugs-at-pre-programmed-rates-a10Emerging Company ProfileProLynx's conjugate linkers increase a drug's duration of action by releasing therapeutics at consistent, preprogrammed rates, which the company thinks can overcome drawbacks of other conjugate technologies.Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/biotech-investor-banker-and-analyst-personnel-changes-a11dhttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/biotech-investor-banker-and-analyst-personnel-changes-a11dFinanceEbb & Flow Venture tracks Brook Byers is now a partner, rather than a general partner, at Kleiner Perkins Caufield & Byers. He will continue to manage existing life sciences investments and will have the option to …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/facebook-investor-peter-thiels-foundation-seeds-first-life-science-startups-a11chttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/facebook-investor-peter-thiels-foundation-seeds-first-life-science-startups-a11cFinanceEbb & Flow Sowing social seeds An early Facebook Inc. investor is trying his hand at seeding life sciences startups. The Thiel Foundation, established and funded by Peter Thiel, last week made its first life …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/gilead-rolls-some-7s-figure-money-raised-in-2012-07http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/gilead-rolls-some-7s-figure-money-raised-in-2012-07FinanceGilead rolls some 7s Money Raised in 2012 Last week, the biotech industry raised $75 million, bringing to $10.8 billion the total raised year-to-date. In 2011, a total of $49.5 billion was raised, including $37.2 …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/gilead-rolls-some-7s-table-commercial-attractions-04http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/gilead-rolls-some-7s-table-commercial-attractions-04FinanceGilead rolls some 7s Commercial attractions GlaxoSmithKline plc's (LSE:GSK; NYSE:GSK) bid for Human Genome Sciences Inc. (NASDAQ:HGSI) may have kindled speculation about other commercial stage biotechs. Of 10 …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/gilead-rolls-some-7s-table-earnings-on-deck-05http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/gilead-rolls-some-7s-table-earnings-on-deck-05FinanceGilead rolls some 7s Earnings on deck At least 24 biotechs and pharmas are slated to report earnings this week. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is expected to swing to profitability on a more than 6X …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/gilead-rolls-some-7s-table-eps-watch-08http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/gilead-rolls-some-7s-table-eps-watch-08FinanceGilead rolls some 7s EPS watch At least seven profitable biotechs and pharmas reported earnings last week. Despite reporting EPS and revenues that beat the Street's estimates, Baxter International Inc. (NYSE:BAX) …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/gsk-offer-for-hgs-sparks-speculation-about-which-biotech-is-next-for-takeout-a11bhttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/gsk-offer-for-hgs-sparks-speculation-about-which-biotech-is-next-for-takeout-a11bFinanceEbb & Flow HGS effect If Human Genome Sciences Inc. (NASDAQ:HGSI) is taken out by GlaxoSmithKline (LSE:GSK; NYSE:GSK), OrbiMed Advisors' Sven Borho expects investors will reinvest the cash in other mid-cap biotechs,…Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/regulatory-clinical-and-other-milestones-a11ehttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/regulatory-clinical-and-other-milestones-a11eFinanceEbb & Flow Regulatory milestones AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) rose $0.67 to $15.93 on Friday after EMA's CHMP issued a positive opinion for an MAA for Rienso ferumoxytol submitted by partner Takeda …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/relieved-wall-street-rewards-gilead-for-new-hcv-data-with-bristol-myers-a11ahttp://www.biocentury.com/biotech-pharma-news/finance/2012-04-23/relieved-wall-street-rewards-gilead-for-new-hcv-data-with-bristol-myers-a11aFinanceTable: Commercial attractions Table: Earnings on deck Figure: Money Raised in 2012 Table: EPS watch Investors exhaled last week after Gilead …Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-23/a-couple-of-bucks-more-table-hgs-pipeline-01http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-23/a-couple-of-bucks-more-table-hgs-pipeline-01StrategyA couple of bucks more HGS pipeline Like its marketed lupus treatment Benlysta belimumab, many of the clinical programs at Human Genome Sciences Inc. (NASDAQ:HGSI) are partnered with suitor GlaxoSmithKline plc (LSE:…Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-23/chiome-taps-consultants-adapts-antibody-platform-to-find-deals-outside-japan-a8http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-23/chiome-taps-consultants-adapts-antibody-platform-to-find-deals-outside-japan-a8StrategyExperienced consultants and adaptive listening have allowed Chiome to crack the code on business development outside of Japan, resulting in three deals in six months.Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-23/evaluating-three-options-for-human-genome-in-wake-of-takeout-bid-by-gsk-a1http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-23/evaluating-three-options-for-human-genome-in-wake-of-takeout-bid-by-gsk-a1StrategyHolding out for more money from GSK seems the most likely scenario for Human Genome Sciences, given the small value ascribed to the biotech's assets outside the partnership and the faint hope for a white knight.Mon, 23 Apr 2012 00:00:00 -0700http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-23/merck-adds-endocytes-vintafolide-to-its-personalized-cancer-portfolio-a6http://www.biocentury.com/biotech-pharma-news/strategy/2012-04-23/merck-adds-endocytes-vintafolide-to-its-personalized-cancer-portfolio-a6StrategyMerck sifted through seemingly conflicting data and concluded vintafolide's PFS benefit in a Phase II trial for platinum-resistant ovarian cancer was robust enough to pay Endocyte $120 million up front for the program.Mon, 23 Apr 2012 00:00:00 -0700